Skip to content
My WebMD Sign In, Sign Up

Melanoma/Skin Cancer Health Center

Font Size

Genetics of Skin Cancer (PDQ®): Genetics - Health Professional Information [NCI] - Changes to This Summary (02 / 08 / 2013)

The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.

Basal Cell Carcinoma

Recommended Related to Melanoma/Skin Cancer

Melanoma/Skin Cancer Clinical Trials

Major pharmaceutical companies continually research and develop new melanoma/skin cancer drugs and treatments, which must be shown to be safe and effective before doctors can prescribe them to patients. Through clinical trials, researchers test the effects of new medications on a group of volunteers with melanoma/skin cancer. Following a strict protocol and using carefully controlled conditions, researchers evaluate the investigational drugs under development and measure the ability of the new drug...

Read the Melanoma/Skin Cancer Clinical Trials article > >

Added text to state that several sets of clinical diagnostic criteria for basal cell nevus syndrome (BCNS) are in use (cited Evans et al. and Veenstra-Knol et al. as references 66 and 68, respectively). Also added text to state that although each set of criteria has advantages and disadvantages, none of the sets have a clearly superior balance of sensitivity and specificity for identifying mutation carriers; PTCH1 mutations are found in 60% to 85% of patients who meet clinical criteria (cited Klein et al. as reference 69).

Added Table 1, Comparison of Diagnostic Criteria for BCNS.

Added text about a 9p22.3 microdeletion syndrome that includes the PTCH1 locus that has been described in ten children, all of whom had facial features of BCNS (cited Muller et al. as reference 109).

Squamous Cell Carcinoma

Added American Cancer Society as reference 1.

Added Doubaj et al. as reference 62.

Added text to state that mutations in C16orf57 are associated with poikiloderma with neutropenia (cited Colombo et al. as reference 151).

Added text to state that mutations in C16orf57 have been identified in individuals with dyskeratosis congenita and poikiloderma with neutropenia, in addition to Rothmund-Thompson syndrome, suggesting that these syndromes are related; however, skin cancer risk in these conditions is not well characterized.

Melanoma

Added text about the Genes, Environment, and Melanoma study, which showed that first-degree relatives of CDKN2A mutation carriers with melanoma had an approximately 50% increased risk of cancers other than melanoma, compared with first-degree relatives of other melanoma patients (cited Mukherjee et al. as reference 88).

This summary is written and maintained by the PDQ Cancer Genetics Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ NCI's Comprehensive Cancer Database pages.

1

WebMD Public Information from the National Cancer Institute

Last Updated: February 25, 2014
This information is not intended to replace the advice of a doctor. Healthwise disclaims any liability for the decisions you make based on this information.
Next Article:

Today on WebMD

Woman checking out tan lines
SLIDESHOW
Cancer Fighting Foods Slideshow
SLIDESHOW
 
what is your cancer risk
HEALTH CHECK
Could Caffeine Help Fight Skin Cancer
VIDEO
 

12 Ways to Protect Your Skin from Melanoma
ARTICLE
precancerous lesions slideshow
SLIDESHOW
 
Do You Know Your Melanoma ABCs
VIDEO
15 Cancer Symptoms Men Ignore
ARTICLE
 

screening tests for men
SLIDESHOW
Vitamin D
SLIDESHOW
 
Is That Mole Skin Cancer
VIDEO
Brilliant sun rays
Quiz
 

WebMD Special Sections